#United States #Los Angeles #Securities Fraud #ImmunityBio #IBRX

ImmunityBio, Inc.'s Shareholders: A Path Forward After Investment Losses

In recent news, investors holding shares of ImmunityBio, Inc. (NASDAQ: IBRX) who have experienced financial losses may have the opportunity to step forward as leaders in a securities fraud class action lawsuit. This announcement comes from Glancy Prongay Wolke & Rotter LLP, a prominent law firm that has taken initiative to rally affected investors.

The Heart of the Issue

The lawsuit addresses serious concerns regarding disclosures made by ImmunityBio between January 19, 2026, and March 24, 2026. Specifically, the allegations are directed at the Company’s management, particularly on statements made by Defendant Soon-Shiong, which are believed to contain exaggerated claims about the capabilities of Anktiva, a drug that has been a focal point in the Company’s portfolio.

Why This Matters: The misleading information could have misguided investors, resulting in unforeseen financial setbacks. As a result, the lawsuit claims that the positive outlook shared by the management on the Company’s business and its operations lacked a solid foundation, which is critical when influencing investor decisions.

Who Can Participate

If you’re an investor who suffered losses during this period, this might be a pivotal moment for you. To become involved in the collective action, interested shareholders are encouraged to act before May 26, 2026, which marks the deadline for becoming a lead plaintiff. It’s crucial for investors to note that no immediate action is necessary; they have the option to engage legal representation at their discretion.

Steps to Learn More

For those wanting clarity on this situation or wishing to know more about the lawsuit process, the announcement lays out clear steps. Investors can reach out via the contact information shared by Glancy Prongay Wolke & Rotter LLP:

• - Contact Person: Charles Linehan, Esq.
• - Address: 1925 Century Park East, Suite 2100, Los Angeles, California 90067
• - Email: [email protected]
• - Phone: 310-201-9150 or Toll-Free at 888-773-9224

It is also shared that any inquiries via email should include necessary identification details like mailing address, phone number, and number of shares purchased.

The Broader Implications

This development highlights the importance of transparency and accuracy in corporate disclosures, particularly for public companies like ImmunityBio. Investors have rights that provide them with avenues to seek justice if they feel misled or wronged by corporate actions.

This situation is not an isolated incident in the landscape of corporate public offerings, and it reinforces the enduring relevance of investor vigilance in tracking the claims and statements made by those in positions of corporate governance.

With the securities fraud lawsuit now taking shape, shareholder activism is set to play a central role in demanding accountability from ImmunityBio’s management. The outcome of this particular case could not only impact the involved parties but also resonate throughout the broader investment community, influencing how transparency is approached in the future. As such, staying informed is crucial for all stakeholders involved.